Role of serial tumor markers in the surveillance for recurrence in endometrial cancer.
The aim of this study is to evaluate the usefulness of tumor markers in the follow-up of patients with endometrial cancer. The sera of 23 patients with elevated pretreatment CA125, CA15.3, and CA19.9 were collected at each follow-up visit and analyzed. Eleven patients had normal posttreatment levels and none of them developed recurrence. Twelve patients had one or more increased tumor markers, 7 (58.3%) of them developed recurrence. Among these seven patients, six had CA125 elevated by at least 10-fold and one had elevated CA19.9. The median lead time between elevation of tumor markers and clinical evidence of recurrence was 6 months. Hence posttreatment elevation of CA125 is a useful predictor for recurrence in patients with elevated pretreatment levels.
Lo
S S
SS
Department of Obstetrics and Gynecology, University of Hong Kong.
Khoo
U S
US
Cheng
D K
DK
Ng
T Y
TY
Wong
L C
LC
Ngan
H Y
HY
D014408:Biomarkers, Tumor; D018394:CA-125 Antigen / Q000097:blood; D018395:CA-19-9 Antigen / Q000097:blood; D016889:Endometrial Neoplasms / Q000175:diagnosis* / Q000601:surgery / Q000628:therapy; D005260:Female; D006801:Humans; D018396:Mucin-1 / Q000097:blood; D011379:Prognosis; D012008:Recurrence
D014408:Biomarkers, Tumor; D018394:CA-125 Antigen; D018395:CA-19-9 Antigen; D018396:Mucin-1